A Failed Phase 3 Drug Shows Signs of Life in Follow-On Data
Nasdaq 24 Sep · 19:00

A Failed Phase 3 Drug Shows Signs of Life in Follow-On Data

Fasedienol missed its Phase 3 goal in June. The open-label follow-on data looks more encouraging — but there was no placebo group to compare against.

Read the story →
Latest
How we work

Every article names the filing or release it came from. Read the source before acting on anything here.

Company in focus Sponsored
Predictiv AI CSE:PAI FWB:7IT

Vertical AI software for logistics, healthcare and aviation.

The AI company working where the real money is made See the full profile →

Predictiv AI has paid PennyStocks.News for this placement. It is advertising, not editorial coverage, and nothing here is investment advice.

Find them before we write about them.
Live screens — most active, gainers, losers and most volatile, US and Canada.
Open screener